Solana Beach, CA, United States of America

Todd Kevin Jones

This inventor holds 110 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 7 EPO patents, primarily in Carbamate Compounds (CPC class C07D-). Top assignees: Ligand Pharmaceuticals, Inc., Wyeth, Abide Therapeutics, Inc.. Active years: 1997-2024.

USPTO Granted Patents = 110 

% Patents Active = 70.9

 

 

Average Co-Inventor Count = 6.0

ph-index = 29

Forward Citations = 2,318(Granted Patents)

Forward Citations (Not Self Cited) = 1,617(Dec 10, 2025)


Inventors with similar research interests:

🔬 See more inventors

Location History:

  • El Cajon, CA (US) (2000 - 2010)
  • Solana Beach, CA (US) (1997 - 2024)
  • San Diego, CA (US) (2013 - 2024)

Company Filing History:


Years Active: 1997-2024

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Carbamate Compounds
Spirocycle Compounds
MAGL Inhibitors
Piperazine Carbamates
Pyrazole Compounds
Inflammation Treatment
Cyclothiocarbamate Derivatives
Indoline Derivatives
Scalable Synthesis
Thio-Oxindole Derivatives
LP-PLA2 Inhibitors
Cyanopyrroles
110 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Todd Kevin Jones

Introduction

Todd Kevin Jones, a prolific inventor based in Solana Beach, California, has made significant strides in the world of pharmaceuticals and chemical compounds. With a remarkable portfolio of 108 patents, his work has contributed to advancements in treatments for various medical conditions, particularly those impacting the nervous system.

Latest Patents

Among Todd Jones' latest innovations is a patent for "Carbamate Compounds and Methods of Making and Using Same." This disclosure details compounds and compositions that serve as modulators of monoacylglycerol lipase (MAGL) and/or alpha/beta hydrolase domain 6 (ABHD6). The compounds are posed as potential medicinal agents and outline processes for their preparation, along with pharmaceutical compositions incorporating these active agents. Another notable patent is for "Crystalline Forms of a MAGL Inhibitor," specifically addressing the MAGL inhibitor 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate, including its crystalline forms and acceptable salts and solvates.

Career Highlights

Todd has built a distinguished career at leading pharmaceutical companies, most notably at Ligand Pharmaceuticals, Inc. His extensive research and dedicated innovation have played a critical role in the development of new therapeutic agents, making him a recognized figure in the pharmaceutical domain.

Collaborations

Throughout his career, Todd has collaborated with notable individuals in the industry, including James Patrick Edwards and Lin Zhi. These partnerships have enhanced the scope of his projects and contributed to his success in patent innovation.

Conclusion

Todd Kevin Jones stands out as a remarkable inventor whose contributions to the fields of pharmacology and chemistry underscore the importance of innovation in addressing critical health issues. His patents not only reflect his inventive spirit but also his commitment to improving patient outcomes through advanced medicinal solutions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…